P01. Female Lung Cancer: An Emerging Issue in Bangladesh - PDF

P02. Increase in Tumour PD-L1 Expression in Non-small Cell Lung Cancer Following Thermal Vapour Ablation is Not Related to Systemic Inflammatory Response - PDF

P03. Comparison of Tumor Mutational Burden in Paired Primary Versus Lung Cancer Brain Metastasis - PDF

P04. Non-Small Cell Lung Cancer (NSCLC) Comprehensive Genomic Profiling: Integrating Expanded Genomic Sequencing Into the Canadian Publicly Funded Health Care Model

P05. Detection of DNA Replication Blocker SLFN11 in Tumor Tissue and Circulating Tumor Cells to Predict Platinum Response in Small Cell Lung Cancer - PDF

P07. Sequencing of TKI With or Without Brain Radiotherapy (RT) in EGFR Mutated or ALK Rearranged Non-small Cell Lung Cancer (NSCLC) with Brain Metastases - PDF

P08. Precision Targeted Therapy for RET-driven NSCLC and Emerging Evidence of Acquired Resistance to RET-Specific Tyrosine Kinase Inhibitors

P09. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients With Lung Adenocarcinoma With EGFR Exon 20 Insertions

P09. Mechanism of Growth-Inhibitory Effect of Pemetrexed Disodium Heptahydrate on Human PC9 (EGFR Exon 19 Deletion) Cells

P10. Inhibitory Effect of Pemetrexed Disodium Heptahydrate on the Growth of KRAS-Dependent A549 Lung Cancer Cells

P11. Expressions of Biomarkers of Malignant Pleural Mesothelioma at Pham Ngoc Thach Hospital, Vietnam in 5 Years From 2015-2019

P04. Non-Small Cell Lung Cancer (NSCLC) Comprehensive Genomic Profiling: Integrating Expanded Genomic Sequencing Into the Canadian Publicly Funded Health Care Model - PDF

P06. The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC - PDF

P07. Management of Advanced Non-small Cell Lung Cancer Patients Harbouring ROS1 Rearrangement- Experience From a Tertiary Cancer Centre in Eastern India - PDF

P08. Precision Targeted Therapy for RET-driven NSCLC and Emerging Evidence of Acquired Resistance to RET-Specific Tyrosine Kinase Inhibitors - PDF

P09. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients With Lung Adenocarcinoma With EGFR Exon 20 Insertions - PDF

P09. Mutated EGFR Pulmonary Adenocarcinoma Experience of the Medical Oncology Department of the Hassan II Hospital University in Fez - PDF

P09. Mechanism of Growth-Inhibitory Effect of Pemetrexed Disodium Heptahydrate on Human PC9 (EGFR Exon 19 Deletion) Cells - PDF

P09. EGFR-TKIs Associated Cardiotoxicity in Lung Cancer Patients: An Analysis of FAERS Database - PDF

P09. Restoring Therapeutic Efficacy of Osimertinib in EGFR-driven NSCLC by Targeting the BMP/Endoglin Signaling Axis - PDF

P10. The Frequency of KRAS Mutations in Brazilian Lung Cancer Patients - PDF

P10. Inhibitory Effect of Pemetrexed Disodium Heptahydrate on the Growth of KRAS-Dependent A549 Lung Cancer Cells - PDF

P11. Correlation Between Histological Subtypes and Prognosis in Patients With Early Stage Lung Adenocarcinoma: An Observational Retrospective Cohort Study - PDF

P11. Expressions of Biomarkers of Malignant Pleural Mesothelioma at Pham Ngoc Thach Hospital, Vietnam in 5 Years From 2015-2019 - PDF